Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

23 Jul 2022

Abstract excerpt

BACKGROUND: Cholangiocarcinoma (CCA) is a primary malignancy of the biliary tract with a dismal prognosis. Recently, several actionable genetic aberrations were identified with significant enrichment in intrahepatic CCA, including FGFR2 gene fusions with a prevalence of 10-15%. Recent clinical data demonstrate that these fusions are druggable in a second-line setting in advanced/metastatic disease and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Fibroblast Growth Factor Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35871236
DOI: 10.1038/s41416-022-01908-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testingPMID 35871236Read ↗

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaSemantic proximity Read ↗

FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice.Semantic proximity Read ↗

Comparative Analysis of Molecular Testing Methods for FGFR2 Fusion/Rearrangement in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomasSemantic proximity Read ↗

FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISHSemantic proximity Read ↗

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.Semantic proximity Read ↗

Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How?Semantic proximity Read ↗

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaSemantic proximity Read ↗

Real-world genomic landscape of FGFR2 amplifications and fusions in solid tumors: analysis of 4,953 patients using clinical-grade NGSSemantic proximity Read ↗

Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.Semantic proximity Read ↗

Current challenges to underpinning the genetic basis for cholangiocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.